- Home
- REBN vs ABP Comparison
REBN vs ABP Comparison
Compare REBN & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- ABP
- Stock Information
- Founded
- REBN 2015
- ABP 2004
- Country
- REBN United States
- ABP United States
- Employees
- REBN N/A
- ABP N/A
- Industry
- REBN Restaurants
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- ABP Health Care
- Exchange
- REBN Nasdaq
- ABP Nasdaq
- Market Cap
- REBN 15.3M
- ABP 17.2M
- IPO Year
- REBN 2022
- ABP N/A
- Fundamental
- Price
- REBN $2.52
- ABP $0.21
- Analyst Decision
- REBN
- ABP Strong Buy
- Analyst Count
- REBN 0
- ABP 1
- Target Price
- REBN N/A
- ABP $4.00
- AVG Volume (30 Days)
- REBN 89.9K
- ABP 3.1M
- Earning Date
- REBN 08-14-2025
- ABP 08-13-2025
- Dividend Yield
- REBN N/A
- ABP N/A
- EPS Growth
- REBN N/A
- ABP N/A
- EPS
- REBN N/A
- ABP N/A
- Revenue
- REBN $6,565,623.00
- ABP $183,000.00
- Revenue This Year
- REBN $335.98
- ABP N/A
- Revenue Next Year
- REBN N/A
- ABP N/A
- P/E Ratio
- REBN N/A
- ABP N/A
- Revenue Growth
- REBN 14.03
- ABP 154.17
- 52 Week Low
- REBN $1.03
- ABP $0.15
- 52 Week High
- REBN $8.30
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- REBN 44.40
- ABP 46.00
- Support Level
- REBN $2.33
- ABP $0.16
- Resistance Level
- REBN $2.89
- ABP $0.19
- Average True Range (ATR)
- REBN 0.18
- ABP 0.02
- MACD
- REBN 0.01
- ABP -0.00
- Stochastic Oscillator
- REBN 36.25
- ABP 46.93
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.